New approaches to target cancer stem cells: Current scenario

dc.contributor.authorInsan, Mayank Bashyal
dc.contributor.authorJaitak, Vikas
dc.contributor.authorInsan, M.B.
dc.contributor.authorJaitak, V.
dc.date.accessioned2017-08-02T07:23:26Z
dc.date.accessioned2024-08-13T12:05:11Z
dc.date.available2017-08-02T07:23:26Z
dc.date.available2024-08-13T12:05:11Z
dc.date.issued2014
dc.description.abstractResistance towards chemotherapy and radiotherapy as well as relapse of cancer is the major obstacle in the treatment of cancer. The main factor behind is cancer stem cells (CSCs) which are more resistant to conventional chemotherapy, radiotherapy and are quite able to regenerate whole new tumor again if remain alive during treatment. Targeting CSCs along with actively dividing cancer cells may significantly contribute to the solution of the problem of resistance and relapse. Various approaches are implemented to eradicate CSCs which include CSC markers specific compounds, Drugs which disturb niche and various inhibitors/modulators of signaling pathways. Hedgehog (Hh), Wnt and Notch pathways are modulated/inhibited using various agents and shown beneficial results in multiple forms of cancer. Many inhibitors/modulators of these pathways have been entered in the clinical trials. MicroRNAs have also been developed as anti CSCs agents. In this review, we have covered current status of CSC targeting therapy based on CSC markers, CSC niche, Hedgehog, Wnt, Notch pathway along with MicroRNA based targeting strategies and possibility of implementation multi-targeted anti-CSC therapy for the better outcome of the results. ? 2014 Bentham Science Publishers.en_US
dc.identifier.citationInsan, M. B., & Jaitak, V. (2014). New approaches to target cancer stem cells: Current scenario. Mini-Reviews in Medicinal Chemistry, 14(1), 20-34. doi: 10.2174/13895575113136660107en_US
dc.identifier.doi10.2174/13895575113136660107
dc.identifier.issn13895575
dc.identifier.urihttps://kr.cup.edu.in/handle/32116/255
dc.identifier.urlhttp://www.eurekaselect.com/117481/article
dc.language.isoenen_US
dc.subjectAldehyde Dehydrogenaseen_US
dc.subjectCd133 Antigenen_US
dc.subjectCd24 Antigenen_US
dc.subjectCd34 Antigenen_US
dc.subjectCd38 Antigenen_US
dc.subjectCell Markeren_US
dc.subjectCurcuminen_US
dc.subjectEpidermal Growth Factoren_US
dc.subjectEpithelial Cell Adhesion Moleculeen_US
dc.subjectFisetinen_US
dc.subjectGrowth Hormoneen_US
dc.subjectHermes Antigenen_US
dc.subjectLeptinen_US
dc.subjectMepacrineen_US
dc.subjectMicrornaen_US
dc.subjectNerve Cell Adhesion Molecule L1en_US
dc.subjectNotch1 Receptoren_US
dc.subjectProlactinen_US
dc.subjectResveratrolen_US
dc.subjectRetinoic Aciden_US
dc.subjectSomatomedin Cen_US
dc.subjectSonic Hedgehog Proteinen_US
dc.subjectSonidegiben_US
dc.subjectSulindacen_US
dc.subjectTelomeraseen_US
dc.subjectThy 1 Antigenen_US
dc.subjectUnindexed Drugen_US
dc.subjectVantictumaben_US
dc.subjectVismodegiben_US
dc.subjectWnt Proteinen_US
dc.subjectApoptosisen_US
dc.subjectCancer Chemotherapyen_US
dc.subjectCancen_US
dc.titleNew approaches to target cancer stem cells: Current scenarioen_US
dc.title.journalMini-Reviews in Medicinal Chemistry
dc.typeReviewen_US

Files

Original bundle

Now showing 1 - 1 of 1
Thumbnail Image
Name:
3.pdf
Size:
514.27 KB
Format:
Adobe Portable Document Format

License bundle

Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.71 KB
Format:
Plain Text
Description: